OBJECTIVES: To determine the efficacy of once-yearly intravenous zoledronic acid (ZOL) 5 mg in reducing risk of clinical vertebral, nonvertebral, and any clinical fractures in elderly osteoporotic postmenopausal women. DESIGN: A post hoc subgroup analysis of pooled data from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly (HORIZON) Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial. SETTING: Multicenter, randomized, double-blind, placebo-controlled trials. PARTICIPANTS: Postmenopausal women (aged > or =75) with documented osteoporosis (T-score < or =-2.5 at femoral neck or >/=1 prevalent vertebral or hip fracture) or a recent hip fracture. INTERVENTION: Patients were randomized to receive an intravenous infusion of ZOL 5 mg (n=1,961) or placebo (n=1,926) at baseline and 12 and 24 months. MEASUREMENTS: Primary endpoints were incidence of clinical vertebral and nonvertebral and any clinical fracture after treatment. RESULTS: At 3 years, incidence of any clinical, clinical vertebral, and nonvertebral fracture were significantly lower in the ZOL group than in the placebo group (10.8% vs 16.6%, 1.1% vs 3.7%, and 9.9% vs 13.7%, respectively) (hazard ratio (HR)=0.65, 95% confidence interval (CI)=0.54-0.78, P<.001; HR=0.34, 95% CI=0.21-0.55, P<.001; and HR=0.73, 95% CI=0.60-0.90, P=.002, respectively). The incidence of hip fracture was lower with ZOL but did not reach statistical significance. The incidence rate of postdose adverse events were higher with ZOL, although the rate of serious adverse events and deaths was comparable between the two groups. CONCLUSION: Once-yearly intravenous ZOL 5 mg was associated with a significant reduction in the risk of new clinical fractures (vertebral and nonvertebral) in elderly postmenopausal women with osteroporosis.
RCT Entities:
OBJECTIVES: To determine the efficacy of once-yearly intravenous zoledronic acid (ZOL) 5 mg in reducing risk of clinical vertebral, nonvertebral, and any clinical fractures in elderly osteoporotic postmenopausal women. DESIGN: A post hoc subgroup analysis of pooled data from the Health Outcome and Reduced Incidence with Zoledronic Acid One Yearly (HORIZON) Pivotal Fracture Trial and the HORIZON Recurrent Fracture Trial. SETTING: Multicenter, randomized, double-blind, placebo-controlled trials. PARTICIPANTS: Postmenopausal women (aged > or =75) with documented osteoporosis (T-score < or =-2.5 at femoral neck or >/=1 prevalent vertebral or hip fracture) or a recent hip fracture. INTERVENTION: Patients were randomized to receive an intravenous infusion of ZOL 5 mg (n=1,961) or placebo (n=1,926) at baseline and 12 and 24 months. MEASUREMENTS: Primary endpoints were incidence of clinical vertebral and nonvertebral and any clinical fracture after treatment. RESULTS: At 3 years, incidence of any clinical, clinical vertebral, and nonvertebral fracture were significantly lower in the ZOL group than in the placebo group (10.8% vs 16.6%, 1.1% vs 3.7%, and 9.9% vs 13.7%, respectively) (hazard ratio (HR)=0.65, 95% confidence interval (CI)=0.54-0.78, P<.001; HR=0.34, 95% CI=0.21-0.55, P<.001; and HR=0.73, 95% CI=0.60-0.90, P=.002, respectively). The incidence of hip fracture was lower with ZOL but did not reach statistical significance. The incidence rate of postdose adverse events were higher with ZOL, although the rate of serious adverse events and deaths was comparable between the two groups. CONCLUSION: Once-yearly intravenous ZOL 5 mg was associated with a significant reduction in the risk of new clinical fractures (vertebral and nonvertebral) in elderly postmenopausal women with osteroporosis.
Authors: J Reginster; H W Minne; O H Sorensen; M Hooper; C Roux; M L Brandi; B Lund; D Ethgen; S Pack; I Roumagnac; R Eastell Journal: Osteoporos Int Date: 2000 Impact factor: 4.507
Authors: E L Hannan; J Magaziner; J J Wang; E A Eastwood; S B Silberzweig; M Gilbert; R S Morrison; M A McLaughlin; G M Orosz; A L Siu Journal: JAMA Date: 2001-06-06 Impact factor: 56.272
Authors: M R McClung; P Geusens; P D Miller; H Zippel; W G Bensen; C Roux; S Adami; I Fogelman; T Diamond; R Eastell; P J Meunier; J Y Reginster Journal: N Engl J Med Date: 2001-02-01 Impact factor: 91.245
Authors: Ian R Reid; Jacques P Brown; Peter Burckhardt; Zebulun Horowitz; Peter Richardson; Ulrich Trechsel; Albert Widmer; Jean-Pierre Devogelaer; Jean-Marc Kaufman; Philippe Jaeger; Jean-Jacques Body; Maria Luisa Brandi; Johann Broell; Raffaele Di Micco; Andrea Riccardo Genazzani; Dieter Felsenberg; Joachim Happ; Michael J Hooper; Jochen Ittner; Georg Leb; Hans Mallmin; Timothy Murray; Sergio Ortolani; Alessandro Rubinacci; Maria Saaf; Goran Samsioe; Leon Verbruggen; Pierre J Meunier Journal: N Engl J Med Date: 2002-02-28 Impact factor: 91.245
Authors: Susan L Greenspan; Subashan Perera; David Nace; Kimberly S Zukowski; Mary A Ferchak; Carroll J Lee; Smita Nayak; Neil M Resnick Journal: J Am Geriatr Soc Date: 2012-02-08 Impact factor: 5.562
Authors: Dennis M Black; Jane A Cauley; Rachel Wagman; Kristine Ensrud; Howard A Fink; Teresa A Hillier; Li-Yung Lui; Steven R Cummings; John T Schousboe; Nicola Napoli Journal: J Bone Miner Res Date: 2017-07-18 Impact factor: 6.741
Authors: Andrew R Zullo; Tingting Zhang; Yoojin Lee; Kevin W McConeghy; Lori A Daiello; Douglas P Kiel; Vincent Mor; Sarah D Berry Journal: J Am Geriatr Soc Date: 2018-12-21 Impact factor: 5.562